Study type: Human research · Status: Verified against declared source

Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching.

Frontiers in medicine · 2021

Study scale: Since 2019, the global pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has influenced almost all countries worldwide.

Abstract only: Open source record

Product or molecular entity relationships

Thymosin Alpha 1: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Objective: Thymosin alpha 1 (Thymosin-α1) is a potential treatment for patients with COVID-19.

Methods

Methods: We retrospectively enrolled 1,388 non-severe patients with COVID-19.

Scale or participants

Since 2019, the global pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has influenced almost all countries worldwide.

Key findings

Objective: Thymosin alpha 1 (Thymosin-α1) is a potential treatment for patients with COVID-19.

Limitations and uncertainty

Conclusion: For non-severe patients with COVID-19, Thymosin-α1 can shorten viral RNA shedding duration and hospital stay but did not prevent COVID-19 progression and reduce COVID-19-related mortality rate.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.